Tuberculosis remains one of the world’s deadliest infectious diseases. The M72/AS01E vaccine candidate has emerged as one of the most promising new tools in decades to prevent pulmonary TB in adults. Dr. Sehulong Robert Moraba played a key role in this landmark research as a Sub-Investigator for the Phase 3 trial (Gates MRI TBV02-301).
This large-scale, randomized, placebo-controlled study (SAHPRA ref: 20230907) assessed the vaccine’s prophylactic efficacy and safety in adolescents and adults in South Africa. Dr. Moraba’s involvement at Setshaba Research Centre contributed to generating the robust data needed to potentially bring the world’s first new TB vaccine in over a century to licensure and deployment.
